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http://www.biomedcentral.com/1472-6890/14/35RESEARCH ARTICLE Open AccessExpression of KOC, S100P, mesothelin and MUC1
in pancreatico-biliary adenocarcinomas:
development and utility of a potential diagnostic
immunohistochemistry panel
Asif Ali1*, Victoria Brown2, Simon Denley3, Nigel B Jamieson3, Jennifer P Morton4, Colin Nixon4, Janet S Graham5,
Owen J Sansom4, C Ross Carter3, Colin J McKay3, Fraser R Duthie6 and Karin A Oien1,6Abstract
Background: Pancreatico-biliary adenocarcinomas (PBA) have a poor prognosis. Diagnosis is usually achieved by
imaging and/or endoscopy with confirmatory cytology. Cytological interpretation can be difficult especially in the
setting of chronic pancreatitis/cholangitis. Immunohistochemistry (IHC) biomarkers could act as an adjunct to
cytology to improve the diagnosis. Thus, we performed a meta-analysis and selected KOC, S100P, mesothelin and
MUC1 for further validation in PBA resection specimens.
Methods: Tissue microarrays containing tumour and normal cores in a ratio of 3:2, from 99 surgically resected PBA
patients, were used for IHC. IHC was performed on an automated platform using antibodies against KOC, S100P,
mesothelin and MUC1. Tissue cores were scored for staining intensity and proportion of tissue stained using a
Histoscore method (range, 0–300). Sensitivity and specificity for individual biomarkers, as well as biomarker panels,
were determined with different cut-offs for positivity and compared by summary receiver operating characteristic
(ROC) curve.
Results: The expression of all four biomarkers was high in PBA versus normal ducts, with a mean Histoscore of
150 vs. 0.4 for KOC, 165 vs. 0.3 for S100P, 115 vs. 0.5 for mesothelin and 200 vs. 14 for MUC1 (p < .0001 for all
comparisons). Five cut-offs were carefully chosen for sensitivity/specificity analysis. Four of these cut-offs, namely
5%, 10% or 20% positive cells and Histoscore 20 were identified using ROC curve analysis and the fifth cut-off was
moderate-strong staining intensity. Using 20% positive cells as a cut-off achieved higher sensitivity/specificity values:
KOC 84%/100%; S100P 83%/100%; mesothelin 88%/92%; and MUC1 89%/63%. Analysis of a panel of KOC, S100P
and mesothelin achieved 100% sensitivity and 99% specificity if at least 2 biomarkers were positive for 10% cut-off;
and 100% sensitivity and specificity for 20% cut-off.
Conclusion: A biomarker panel of KOC, S100P and mesothelin with at least 2 biomarkers positive was found to be
an optimum panel with both 10% and 20% cut-offs in resection specimens from patients with PBA.
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Pancreatic ductal adenocarcinoma (PDAC) is the fifth most
common cause of cancer death in the UK with a 5-year
survival of only 2% [1]. This poor prognosis is partly due to
late clinical presentation with advanced disease, when the
treatment options are limited and relatively ineffective [2].
Surgical resection is the only curative option but is only
available to 15-20% patients with localised disease [3,4].
The remainder with locally advanced and/or metastatic
disease are offered palliative chemotherapy, radiotherapy
and/or best supportive management [2,3]. Adenocarcin-
omas of the head of pancreas and extra-hepatic cholan-
giocarcinomas (CCC) present similarly most often with
jaundice, pain or weight loss [5]. Morphological similarities
in addition to generally poor prognosis for both diseases
enable PDAC to be grouped with extrahepatic CCC to
form so-called pancreatico-biliary adenocarcinomas (PBA).
Diagnosis of PBA relies upon a combination of radio-
logical and cytology or pathology findings [6-10]. Con-
firmatory tissue diagnosis is necessary before chemotherapy
or radiotherapy treatment, however a biopsy specimen is
not always required for resection when the suspicion of
cancer is high; as generally, the resection will provide
therapeutic benefit, and substantially delaying surgery to
confirm a diagnosis may deny potentially curative treat-
ment [9,11-15].
Endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) is normally used to obtain cytological samples
from pancreatic mass lesions, while endoscopic retrograde
cholangio-pancreato-graphy (ERCP) biliary brushings are
used for cytology collection from strictures of pancreatico-
biliary (PB) ducts [16-18]. Cytological analysis requires the
distinction of malignant PB epithelial cells from reactive
pancreatic and bile duct cells as well as other gastro-
intestinal contaminants. This task requires tremendous
expertise and can be difficult for both quantitative and
qualitative reasons [19]. Quantitatively, the cytological
sample obtained may be of low cellularity with few, or even
no malignant epithelial cells amongst a variety of cell types.
Qualitatively, PBA cells can be morphologically similar to
reactive PB cells, especially in well-differentiated adenocar-
cinomas. Chronic reactive changes arising from atrophy or
inflammation in pancreatitis or cholangitis are common,
and also make diagnosis of adenocarcinoma difficult.
Expressing these issues statistically, the reported sensitiv-
ity of EUS-FNA ranges from 78%-95% with specificity re-
ported to be 75-100% [17,18,20-25]. Though the specificity
of biliary brush cytology is high, the sensitivity can be low
with ranges of 46% to 73% reported [10,16,26,27]. The sen-
sitivity of EUS-FNA cytology decreases to 62% in chronic
pancreatitis and to only 50% in cases of chronic pancrea-
titis with obstructive jaundice [28]. Thus, a tissue diagnosis
is not achieved in a significant proportion of PBA cases.
Hence, an unmet clinical need exists for the diagnosisof PBA from cytological samples obtained at EUS-FNA
and ERCP.
One potential way of improving cytological diagnosis
is to use immunohistochemical (IHC) biomarkers as an
adjunct to cytology in difficult to diagnose cases. IHC is
a technique widely used in diagnostic pathology that en-
ables the observation and localisation of protein expres-
sion simultaneously in tissue and cellular compartments
[29]. Diagnostic IHC biomarkers have been investigated
both as single biomarkers and as part of biomarker
panels to improve the diagnosis of PDAC, but to date
none has entered into routine clinical practice [30-37].
We performed a meta-analysis of potential PDAC IHC
diagnostic biomarkers [38] aiming to generate a list of
biomarkers assessed in either surgical or cytology speci-
mens, where PDAC was compared with normal pancreas
and/or chronic pancreatitis. Meta-analytical results showed
KOC, S100P, mesothelin and MUC1 to be high-ranking
candidates. These biomarkers have not entered into rou-
tine clinical practice partly because they were investigated
in separate studies with relatively small sample sizes and
without uniform and clinically appropriate thresholds for
positivity.
We sought to investigate the utility of these four candi-
date biomarkers in the characterisation of PBA, including
both PDAC and CCC. CCC has been included because it
often enters the clinical and pathological differential diag-
nosis; and its positive biomarkers are generally shared with
PDAC [39-42]. The aim was to identify a clinically useful
diagnostic biomarker or panel of biomarkers with a robust
cut-off for positivity that could potentially be taken for-
ward for validation in PBA cytology samples.
A biomarker panel of KOC, S100P and mesothelin
with at least 2 biomarkers positive was found to be an
optimum panel with both 10% and 20% cut-off achieving
almost 100% sensitivity and specificity in resection speci-
mens from patients with PBA.
Methods
Tissue Microarrays
Histological sections from tissue microarrays (TMAs)
containing samples from 99 surgically resected PBA pa-
tients (PDAC = 85, CCC = 14) were used for IHC. All re-
sectional surgery was performed in the West of Scotland
Pancreatic Unit, Glasgow Royal Infirmary, UK, during a
10-year period (1st June 1995 to 31st July 2004). Forma-
lin fixed paraffin embedded (FFPE) tumour specimens
were archived in the Department of Pathology, Glasgow
Royal Infirmary and were used for the construction of
TMAs. The construction and use of these TMAs has
been previously described [43]. Ethical approval has been
granted by the North Glasgow University Hospitals NHS
Trust Ethics Committee and by the National Health Ser-
vice Greater Glasgow and Clyde Ethics Committee. This
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specimens, where the patients were not given the oppor-
tunity to donate their tissue. These TMAs contain five
tissue cores (3 tumours and 2 normal) for each patient.
Tumour cores are adenocarcinoma cores from PBA pa-
tients, whereas normal cores are from adjacent normal
pancreatic ducts and acini.
Immunohistochemistry
IHC was performed for KOC, S100P, mesothelin and
MUC1 on our TMA cohort, on an automated platform.
Details of the antibodies, antibody concentrations and
IHC conditions are shown in Table 1.
Scoring of tissue specimens
Stained TMA sections were scanned (Hamamatsu Slide
Scanner) and images uploaded in Distiller 2.2 (Leica Bio-
systems). Microscopic analysis was undertaken blinded to
diagnosis or other parameters. IHC staining of all cores
was assessed by one author (AA); a second author (KAO)
double-scored approximately 15% of cores, in a blinded
fashion, as audit. All scores were exported in an Excel
spreadsheet from Distiller 2.2 for analysis. A semi-
quantitative Histoscore [0 ×% negative cells + 1 ×% weakly
stained cells + 2 ×% moderately stained cells + 3 ×% strongly
stained cells] was generated for statistical analysis. This
Histoscore thus has a range of possible scores between 0
and 300.
Statistics and data analysis
The mean expression of each biomarker in the PBA
tumour cores was compared with the mean expression
in normal tissue cores. Statistical significance was calcu-
lated using the independent sample t-test to generate
the p value. The independent sample t test was used ra-
ther than the paired sample t test because a full set of
matching tumour and normal tissue cores was not avail-
able for approximately 5% of patients. This was due to
loss of tissue cores during processing, which is expected
in a proportion of samples. Sensitivity/specificity ana-
lyses were carried out for biomarkers, both individually
and in panels of 2–4 biomarkers, and compared. We
used two different panel approaches for sensitivity/speci-
ficity analysis. One approach assigns the case into theTable 1 Details of the immunohistochemistry methodology fo
Antibody Company Clone of antibody Host animal
KOC/IMP3 DAKO L523S, 69.1 Mouse Monoclonal
S100P BD Biosciences 16 Mouse monoclonal
Mesothelin Novocastra 5B2 Mouse monoclonal
MUC1 Novocastra MA695 Mouse monoclonal
*HIER= Heat Induced epitope retrieval.positive category if the tumour expresses only one bio-
marker in the panel. The other approach assigns the
case into the positive category if the tumour shows
staining for at least 2 biomarkers in the panel.
A combined summary receiver operating characteristic
(SROC) curve was generated to compare different panels
of biomarkers. P value <0.05 was considered statistically
significant. SPSS-19 and RevMan-5.1 were used for stat-
istical analysis.Results
We first performed IHC for each of the four biomarkers
on microarrays of normal and tumour tissue from pa-
tients with PBA. To fully assess the clinical usefulness of
these biomarkers we wanted to analyse the expression of
all four biomarkers in PBA versus normal tissue. More-
over, by combining various biomarkers in panels, we
hypothesised that we would be able to determine the
combination of biomarkers that would deliver the best
diagnostic sensitivity and specificity.Staining characteristics of biomarkers
For each marker assessed in the PB TMAs, IHC staining
was seen only in epithelial cells. As expected, KOC ex-
pression was observed in the cytoplasm; S100P was
expressed in the cytoplasm and nucleus, while mesothe-
lin and MUC1 expression was cytoplasmic and mem-
branous (Figure 1). In general, we observed moderate to
strong intensity of staining for KOC, mesothelin, S100P
and MUC1 in PBA. Moreover, for all four biomarkers
we observed significantly higher expression in tumour
versus normal tissue (non-neoplastic ducts or pancreatic
acinar tissue). The mean percentage positivity for bio-
markers in tumour vs. normal tissue was as follows: for
KOC 74% vs. 0.4%; for S100P 75% vs. 0.3%; for mesothe-
lin 75% vs. 4%; and for MUC1 75% vs. 18% (Table 2, p <
0.0001 for all tumour vs. normal comparisons). When
scored simply as the percentage of positive staining cells
per tumour core, we observed similar results for all four
biomarkers in tumour tissue. As shown in Table 2, the
mean percentage of positive carcinoma cells in tumour
tissue was 74% for KOC, 75% for S100P, 73% for
mesothelin and 75% for MUC1.r four antibodies
Antigen retrieval Antibody
dilution
Incubation
temperature
Duration of
incubation
HIER* (Citrate buffer PH 6) 1:50 25°C 60 min
Proteinase K (10 minutes) 1:100 25°C 60 min
HIER (Citrate buffer PH 6) 1:20 25°C 60 min
HIER (Citrate buffer PH 6) 1:200 25°C 60 min
Figure 1 Representative images of staining of all four biomarkers in normal tissue (normal pancreatic tissue) and range of staining
intensities (weak, moderate and strong) in tumour tissue from tissue microarray cores.
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takes into account both the extent of expression across
the tissue core, and the staining intensity, we were able
more to perform a more comprehensive analysis of our
biomarkers. Utilizing this method to score the degree
and intensity of staining revealed variance of expression
of the different biomarkers. As shown in Table 2, the
mean tumour tissue versus mean normal tissue Histo-
score for MUC1 was 193 vs. 48, while for S100P, KOC
and mesothelin, the mean tumour tissue versus mean
normal tissue Histoscores were 165 vs. 0.3, 150 vs. 0.5
and 115 vs. 4 respectively.Although one biomarker, MUC1, was expressed in nor-
mal tissue as evidenced by the mean percentage positivity
of 16% of normal cells in normal tissues, the expression of
the other three biomarkers was very low in normal tissue
(Table 2). Furthermore, there were no significant differ-
ences in biomarker expression between normal ducts only
and normal ducts and acini together (see Additional file 1).
Thus, IHC staining using these markers could greatly
facilitate interpretation of cytology samples.
Biomarkers expression was also assessed in PDAC
compared to CCC as shown in Additional file 2. The ex-
pression of all four biomarkers is similar in PDAC and
Table 2 Summary statistics of KOC, S100P, mesothelin
and MUC1 expression on a per core basis comparing
pancreatico-biliary adenocarcinomas with normal tissue
Biomarkers Pancreaticobiliary
adenocarcinoma
Normal
tissue
P value
KOC
Positivity* Mean 74% 0.4% <0.0001
Median 100% 0%
Histoscore Mean 150 0.5 <0.0001
Median 180 0
S100P
Positivity Mean 75% 0.3% <0.0001
Median 100% 0%
Histoscore Mean 165 0.3 <0.0001
Median 180 0
Mesothelin
Positivity Mean 73% 4% <0.0001
Median 90% 0%
Histoscore Mean 115 4 <0.0001
Median 110 0
MUC1
Positivity Mean 75% 18% <0.0001
Median 90% 10%
Histoscore Mean 193 48 <0.0001
Median 200 30
Note: *Positivity (percentage of positive cells with any staining intensity in
tumour and normal tissue); P value (shows the statistical significance of the
difference in expression of a biomarker in tumour vs. normal tissue); Positivity
range (0–100), Histoscore range (0–300).
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ence in the mean expression of biomarkers between
these two tumour types (p > 0.05, independent sample t
test). Therefore, for sensitivity and specificity analyses
PDAC and CCC were grouped as PBA.
Sensitivity and specificity analysis
Establishing cut-offs from ROC curve analysis
The sensitivity and specificity of these four biomarkers
were evaluated using five cut-offs (thresholds) for posi-
tivity as follows: 5% positive cells of any staining inten-
sity; 10% positive cells of any staining intensity; 20%
positive cells of any staining intensity; moderate or
strong staining of any cells; and Histoscore ≥20. Three
of these cut-offs were based on percentage of positive
cells and identified by ROC curve analysis. The sensitiv-
ity of each biomarker was plotted against 1 – specificity,
and ROC curves with coordinates were generated for all
four biomarkers (Figure 2). The area under the curve
was 0.93 (0.88-0.97, 95% CI) for KOC, 0.92 (0.85-0.99,
95% CI) for S100P, 0.95 (0.92-0.99, 95% CI) for mesothe-
lin, and 0.87 (0.81-0.93, 95% CI) for MUC1. Based onpercentage of positive cells in the tumour compared
with normal cores, ROC curve analysis allowed us to as-
sess potential cut-offs, from 5% positive cells to 95%
positive cells, with their corresponding sensitivity and
specificity values for all four biomarkers (Figure 2 and
Additional file 3). Three best cut-offs; 5%; 10% or 20% of
positive cells of any staining intensity were selected
based on their sensitivity and specificity values.
The fourth cut-off was based on moderate to strong
staining intensity (+2/+3 staining) in any of the cells.
This was selected as moderate to strong staining was ex-
pected to be easily interpreted by pathologists. Interest-
ingly, cases with +2/+3 staining for all four biomarkers
have more than 20% cells positive for each of the four
biomarkers. Indeed patients with +2/+3 staining have
only 5 cases with less than 50% of cells positive for
MUC1, 2 cases in which KOC was expressed in fewer
than 50% of cells, and only 1 case each for mesothelin
and S100P staining with less than 50% positivity.
The fifth cut-off was based on a Histoscore value of 20
(HS20), and was selected from ROC curve analysis (see
Additional file 4).Sensitivity and specificity of candidate biomarkers
The sensitivities and specificities of all four biomarkers
were calculated using these five cut-offs, as shown in
Figure 3. KOC expression appears to show reasonably
high sensitivity and specificity for all cut-offs except for
the cut-off based on +2/+3 staining, which resulted in
low sensitivity of only 67%. The 20% positive cells cut-
off achieves marginally better sensitivity (84%) and speci-
ficity (100%) values compared with other cut-offs for
KOC (Figure 3A). S100P appears to have similar sensi-
tivity and specificity values for all five cut-offs with the
20% cut-off again achieving better combination of speci-
ficity and sensitivity, with values of 83% sensitivity and
100% specificity (Figure 3B).
Applying the five cuts-offs to the analysis of mesothe-
lin expression resulted in significantly different sensitiv-
ity and specificity values, however, the best combination
was again achieved using the 20% cut-off, with 88% sen-
sitivity and 92% specificity (Figure 3C). Although the
sensitivity of MUC1 as biomarker is high across all cut-
offs, its specificity is unacceptably low for all cut-offs,
with a range of 18%-63% compromising the diagnostic
accuracy of MUC1 (Figure 3D).Sensitivity and specificity analysis using biomarker panels
We next wanted to assess the sensitivity and specificity
achieved using panels of biomarkers. The 10% and 20%
cut-offs were selected for this investigation, based on
their diagnostic performance.
Figure 2 ROC curves based on percentage of cells positive for any staining (weak, moderate or strong), in tumour and normal cases,
for four biomarkers (A) KOC, (B) S100P, C) mesothelin and D) MUC1.
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We first assessed the sensitivity and specificity achieved
when one biomarker in a panel is positive, using four dif-
ferent panels (Table 3). These panels were: a panel com-
prising all four biomarkers; a panel of three biomarkers
(KOC, S100P and mesothelin); and two panels of two bio-
markers (KOC and mesothelin, KOC and S100P). As ex-
pected, a panel of all four biomarkers achieved very low
specificity of 40% and 65% respectively for 10% and 20%
cut-offs, due to the low specificity of MUC1 as a bio-
marker. A panel of KOC, S100P and mesothelin achieved
sensitivity/specificity of 100%/88% for the 10% cut-off and
99%/94% for the 20% cut-off. A panel of KOC and
mesothelin achieved sensitivity/specificity of 97%/87% and
96%/93% for the 10% cut-off and 20% cut-offs, respect-
ively. Finally, a panel of KOC and S100P achieved sensitiv-
ity/specificity of 98%/96% for the 10% cut-off and 99%/
99% for the 20% cut-off.
These panels were compared by combined SROC
curve, using both the 10% cut-off (Figure 4A) and 20%
cut-offs (Figure 4B). The combined SROC curve shows
that a panel of KOC and S100P is superior to the other
panels for both 10% and 20% cut-offs.Analysis based on two or more positive biomarkers in a
panel
Finally, one biomarker panel comprising KOC, S100P
and mesothelin was tested for sensitivity and specificity
when at least 2 biomarkers in the panel are positive.
This panel achieved almost 100% sensitivity/specificity
for both 10% and 20% cut-offs (Table 3). Taken together,
our results show that this panel could be used to im-
prove diagnosis of PBA in difficult to diagnose cases.
Discussion
Four potentially diagnostic biomarkers, KOC, S100P,
mesothelin and MUC1, were investigated in a relatively
large cohort of PB patients (n = 99). The expression levels
of KOC, S100P and mesothelin were high in tumour tissue
compared with normal tissue. The diagnostic accuracy
(sensitivity and specificity) of KOC and S100P individually
was greater than that of mesothelin and MUC1. A panel
of KOC, S100P and mesothelin with at least 2 biomarkers
positive achieved almost perfect diagnostic accuracy in the
differentiation of carcinoma from normal tissue.
IHC biomarkers have previously been investigated in sur-
gical and cytological cohorts but none is yet routinely used
Figure 3 Sensitivity and specificity analysis of biomarkers for the diagnosis of pancreatico-biliary adenocarcinoma compared to
normal tissue, based on five cut-offs for positivity: 5% positive cells of any staining intensity; 10% positive cells of any staining
intensity; 20% positive cells of any staining intensity; 2 OR 3 intensity i.e. moderate or strong staining of cells; and Histoscore 20.
Analysis is presented for A) KOC, B) S100P, C) mesothelin and D) MUC1.
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are six significant reasons delaying the clinical translation
of diagnostic biomarkers in PBA and other cancers. These
reasons and our approach to address them are outlined
below.
Firstly, a plethora of research exists on diagnostic IHC
biomarkers coming from the bench assessed in pilot
studies. There are many excellent papers but fewer valid-
ation studies for biomarkers that have shown promising
results. Clearly, validation is important for future clinical
application. Therefore, we performed a meta-analysis on
diagnostic IHC biomarkers for PDAC [38], to review,
quantify and assess the performance of already existing
biomarkers and to try and identify superior candidate
biomarkers.
The biomarkers derived from the meta-analysis in
PDAC were applied in our study to both PDAC and
CCC samples. Separate meta-analysis was not performed
for CCC, because there are relatively few publishedpapers on biomarkers in CCC (approximately 20-fold
fewer than for PDAC; PubMed search in June 2014, un-
published data). However, those papers which are avail-
able for CCC suggest that the biomarker expression
profile is similar to PDAC. To our knowledge, all of the
known positive biomarkers for PDAC (versus corre-
sponding normal tissue), including MUC1, P53, CK17,
mesothelin, fascin, MUC4, 14-3-3σ and prostate stem
cell antigen, show similar IHC expression in CCC (ver-
sus corresponding normal tissue) [39-42].
For these reasons, we focused on PDAC for the identifi-
cation of potential diagnostic biomarkers then tested the
resulting candidates in TMAs containing tissue from both
PDAC and CCC using IHC. From our meta-analysis, we
selected KOC [36,37,44,47], S100P [32,35,48], mesothelin
[30,49,50] and MUC1 [31,40,51] for investigation.
We found that expression of these biomarkers was simi-
lar in PDAC and CCC (Additional File 2): our results
therefore supporting the previous literature [39-42].
Table 3 Panels of biomarkers used for analysis of
specificity and sensitivity, using 10% positive cells and
20% positive cells as cut-off thresholds for positivity
10% positive cells as cut-off
Panels Sensitivity Specificity
KOC, S100P, Mesothelin, MUC1 100% 40%
KOC, S100P, Mesothelin 100% 88%
KOC, Mesothelin 97% 87%
KOC, S100P 98% 96%
KOC, S100P, Mesothelin* 100% 99%
20% positive cells as cut-off
Panels Sensitivity Specificity
KOC, S100P, Mesothelin, MUC1 100% 65%
KOC, S100P, Mesothelin 99% 94%
KOC, Mesothelin 96% 93%
KOC, S100P 99% 99%
KOC, S100P, Mesothelin* 100% 100%
Note: *At least 2 biomarkers required to be positive in this panel. In the rest of
the panels only one biomarker was required to be positive in a panel.
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nostic biomarkers for PDAC is relatively small (median
sample size, n = 48 from 57 articles). Moreover, matched
normal tissue for most of the carcinoma case is not al-
ways available, leading to even smaller sample sizes for
calculating biomarker specificity. Therefore, statistical
power is relatively low and subsequently potentially use-
ful biomarkers may be ignored. Our relatively largerFigure 4 *Combined Summary ROC curves for 10% (A) and 20% (B) c
panel. Four panels of biomarkers were compared. Panel 1 - KOC, S100P, M
S100P; Panel 4 - KOC, Mesothelin. *Summary ROC curves plot sensitivity ag
sensitivity and specificity of a panel. Combined Summary ROC curves comp
line at the top left corner shows the biomarker which is most accurate com
most accurate panel to be identified.sample size of 99 PBA cases (n = 99 adenocarcinomas
and n = 99 matched normal tissue for each case; total
n = 198) provided a solid platform for investigating
these diagnostic IHC biomarkers.
Third, the lack of a standardised scoring system and
absence of a uniform cut-off (threshold) for the inter-
pretation of IHC remains problematic. Thus, researchers
use a variety of traditional and novel scoring systems
and diverse cut-offs, making the adoption of scoring sys-
tems and cut-offs potentially challenging for the patholo-
gists [30,35,37,41,46,49,52-54]. We systematically chose
cut-offs from ROC curve analysis to fully explore the
diagnostic potential of all four biomarkers. These cut-
offs provide an opportunity for the pathologists to select
the best threshold that is more clinically applicable and
has the potential to be routinely used in pathology.
Three of these cut-offs are based on proportion of posi-
tive cells (5%, 10% and 20%) with staining of any inten-
sity. The fourth cut-off is based on any proportion of
cells exhibiting moderate and strong staining intensity,
and the fifth cut-off is based on a Histoscore of 20. Not-
ably, the 20% cut-off and Histoscore 20 provide reason-
able sensitivity and specificity values for PBA diagnosis.
A higher Histoscore value could potentially lead to more
false negatives in tumour cases, therefore, a low cut-off
value of 20 was chosen. Clearly, this cut-off will remove
the probability of false negative and should increase the
diagnostic confidence of pathologists for higher Histo-
score values. For example, a Histoscore value of 200 for
a biomarker in a suspicious case might help theut-offs if only one biomarker was required to be positive in a
esothelin and MUC1; Panel 2 - KOC, S100P, Mesothelin; Panel 3 - KOC,
ainst specificity and draw a summary line depicting combined
are different panels to show the most “accurate” panel. The summary
pared to others lying lower and further to the right. This enables the
Ali et al. BMC Clinical Pathology 2014, 14:35 Page 9 of 11
http://www.biomedcentral.com/1472-6890/14/35pathologist to diagnose a tumour with confidence and
with a much higher specificity.
Fourth, most of the IHC diagnostic biomarkers have
been investigated individually [32,46,47,55,56], with few
studies reporting the utility of biomarker panels [30,36].
We carefully selected candidate biomarkers reported in
different studies (KOC, mesothelin, S100P and MUC1)
for investigation in a single experimental setting. Investi-
gation of these biomarkers in a single cohort gave us the
opportunity to compare biomarkers, and then further
explore their diagnostic accuracy in a panel. Expectation
from an ideal diagnostic biomarker is its ability to iden-
tify the diseased population (sensitivity) and exclude the
normal population (specificity) in 100% cases. However,
no single biomarker is 100% perfect; therefore these bio-
markers were investigated in various combinations, to
select an optimum panel for potential clinical applica-
tion. For example, the individual sensitivity/specificity of
KOC and S100P at a cut-off of 20% positive cells was
84%/100% and 83%/100% respectively. However, using a
panel of KOC and S100P improved sensitivity to 99%
without compromising the specificity (99%).
Furthermore, using a panel of KOC, S100P and mesothe-
lin with at least 2 positive biomarkers achieved almost
100% sensitivity and specificity for both 10% and 20%
cut-offs. This approach would assign a patient into the
tumour positive category if 2 or more biomarkers are posi-
tive, possibly giving more assurance to the pathologist be-
fore assigning patient into positive category. Moreover, a
combination of KOC, S100P and mesothelin antibodies
should stain all major cellular compartments (cell mem-
brane, nucleus and cytoplasm). Clinically, a cytology sample
comprises a mixed population of cells and this panel will
stain malignant cells more intensely making the interpret-
ation of IHC convenient for the pathologist. The possible
additional advantage of KOC is that it is not expressed in
the contaminating gastrointestinal epithelial cells that are
usually present in cytological samples [44,57]. Our data also
confirm the lack of expression of KOC in normal duode-
num. Taken together, our results reinforce the reported
sensitivity/specificity values for KOC, S100P and mesothe-
lin [30,35,37,57] and further explores their utility as a panel.
The fifth reason is that different research groups use dif-
ferent IHC experimental conditions, primary antibodies,
clones, dilutions and manual/automated platforms that
could potentially lead to a diverse range of sensitivity and
specificity values for biomarkers [30,45,54,58-60]. We
thoroughly searched the literature for IHC parameters for
KOC, S100P, mesothelin and MUC1. Those IHC parame-
ters that achieved superior diagnostic accuracy were se-
lected and further optimised in our histology laboratory
before staining our cohort.
Finally, an important requirement for biomarker trans-
lation to the clinic is independent validation with theaim of improving already existing diagnosis. Purposeful
validation in surgical and cytological tissue from PBA
cohorts and subsequent prospective clinical study on
cytological samples is deficient. Therefore, as an import-
ant step for potential clinical translation we investigated
KOC, S100P, mesothelin and MUC1 in a surgical cohort
of PBA patients with promising results for KOC, S100P
and mesothelin as a biomarker panel.
The next step forward is to possibly investigate these
biomarkers in a retrospective and then in a prospective
cohort of cytology samples. This manuscript systematically
attempted to answer all six major reasons hindering the
clinical translation of diagnostic IHC biomarkers for pan-
creatic cancer. It also provides future direction and work
packages to be performed before these diagnostic bio-
markers can be used in day-to-day pathology practice.Conclusions
Our results demonstrate that a biomarker panel of KOC,
S100P and mesothelin is capable of categorising PB malig-
nancy with high diagnostic accuracy in resection specimens.
We plan to investigate this panel in archival cytological
samples. As an adjunct to cytology, this panel has the po-
tential to augment the categorisation for challenging diag-
nostic cases in routine clinical practice.To our knowledge,
this is the first study of PB literature that identified cut-offs
systematically for diagnostic purposes and used stringent
panels to identify an optimum biomarker panel.Additional files
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